LncRNA-MSC-AS1 Inhibits the Ovarian Cancer Progression by Targeting MiR-425-5p

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2021 Aug 29

PMID 34454554

Citations 11

Authors

Yinling Zhao

Donglan Yuan

Dandan Zhu

Tianhui Xu

Aihua Huang

Li Jiang

Chiwen Liu

Hua Qian

Xinhua Bu

Affiliations

Soon will be listed here.

Abstract

Background: Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) were reported to be aberrantly expressed and related to the pathogenesis of ovarian cancer. However, the role and regulatory mechanism of MSC-AS1 in ovarian cancer has yet to be fully elucidated.

Methods: Expression of lncRNA MSC-AS1 (MSC-AS1) and microRNA-425-5p (miR-425-5p) in the ovarian cancer tissue samples and cell lines was examined by quantitative real-time polymerase chain reaction (qRT-PCR). The functions of MSC-AS1 on ovarian cancer cell proliferation, cell cycle and apoptosis were determined using MTT, colony formation and flow cytometry analyses. The protein expression levels were evaluated using western blot assay. The targeting relationship MSC-AS1 and miR-425-5p was verified via dual-luciferase reporter assay.

Results: MSC-AS1 expression level was lowly expressed, while miR-425-5p level was highly in ovarian cancer tissues and cells. Elevation of MSC-AS1 has the ability to significantly inhibit cell proliferation and facilitate cell apoptosis in SKOV3 and A2780 cells. Moreover, MSC-AS1 targeted and negatively modulated miR-425-5p. MiR-425-5p up-regulation has been proved to partially reverse the tumor suppressive function of MSC-AS1 overexpression CONCLUSION: MSC-AS1 sponged miR-425-5p to inhibit the ovarian cancer progression. These findings may provide a promising therapeutic target for the treatment of ovarian cancer.

Citing Articles

LINC00899 suppresses the progression of triple-negative breast cancer via the miRNA-425/PTEN axis and is a biomarker for neoadjuvant chemotherapy efficacy.

Niu L, Bai Y, Yu M, Sun X J Cancer. 2025; 16(5):1647-1655.

PMID: 39991583 PMC: 11843232. DOI: 10.7150/jca.100619.

Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications.

Hushmandi K, Klionsky D, Aref A, Bonyadi M, Reiter R, Nabavi N Noncoding RNA Res. 2024; 9(4):1159-1177.

PMID: 39022677 PMC: 11250880. DOI: 10.1016/j.ncrna.2024.05.008.

CircUBE2D2 regulates HMGB1 through miR-885-5p to promote ovarian cancer malignancy.

Yan R, Zeng S, Gao F, Li L, Xiao X Clinics (Sao Paulo). 2024; 79:100391.

PMID: 38848634 PMC: 11214364. DOI: 10.1016/j.clinsp.2024.100391.

The Effect of Race/Ethnicity and MED12 Mutation on the Expression of Long Non-Coding RNAs in Uterine Leiomyoma and Myometrium.

Chuang T, Ton N, Rysling S, Boos D, Khorram O Int J Mol Sci. 2024; 25(2).

PMID: 38279317 PMC: 10816284. DOI: 10.3390/ijms25021307.

CENPA knockdown restrains cell progression and tumor growth in breast cancer by reducing PLA2R1 promoter methylation and modulating PLA2R1/HHEX axis.

Wu G, Fan Z, Li X Cell Mol Life Sci. 2024; 81(1):27.

PMID: 38212546 PMC: 11072086. DOI: 10.1007/s00018-023-05063-5.

References

Zhang L, Zhao G, Ji S, Yuan Q, Zhou H . Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142. Med Sci Monit. 2020; 26:e921594. PMC: 7081928. DOI: 10.12659/MSM.921594. View

Hu Z, Li L, Cheng P, Liu Q, Zheng X, Peng F . lncRNA MSC-AS1 activates Wnt/β-catenin signaling pathway to modulate cell proliferation and migration in kidney renal clear cell carcinoma via miR-3924/WNT5A. J Cell Biochem. 2020; 121(10):4085-4093. DOI: 10.1002/jcb.29594. View

Zhang Z, Li Y, Fan L, Zhao Q, Tan B, Li Z . microRNA-425-5p is upregulated in human gastric cancer and contributes to invasion and metastasis and . Exp Ther Med. 2015; 9(5):1617-1622. PMC: 4471687. DOI: 10.3892/etm.2015.2318. View

Reed N, Symonds R . Ovarian Cancer. Clin Oncol (R Coll Radiol). 2018; 30(8):461-462. DOI: 10.1016/j.clon.2018.06.002. View

Xu C, Shao Y, Xia T, Yang Y, Dai J, Luo L . lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumour Biol. 2014; 35(10):9701-6. DOI: 10.1007/s13277-014-2274-5. View

Wu H, Tian X, Zhu C . Knockdown of lncRNA PVT1 inhibits prostate cancer progression in vitro and in vivo by the suppression of KIF23 through stimulating miR-15a-5p. Cancer Cell Int. 2020; 20:283. PMC: 7330980. DOI: 10.1186/s12935-020-01363-z. View

Zhang L, Zhang J, Zhou H, Dai T, Guo F, Xu S . MicroRNA-425-5p promotes breast cancer cell growth by inducing PI3K/AKT signaling. Kaohsiung J Med Sci. 2019; 36(4):250-256. DOI: 10.1002/kjm2.12148. View

Liu D, Zhang H, Cui M, Chen C, Feng Y . Hsa-miR-425-5p promotes tumor growth and metastasis by activating the CTNND1-mediated β-catenin pathway and EMT in colorectal cancer. Cell Cycle. 2020; 19(15):1917-1927. PMC: 7469528. DOI: 10.1080/15384101.2020.1783058. View

Wang H, Tan Z, Hu H, Liu H, Wu T, Zheng C . microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer. 2019; 19(1):738. PMC: 6661096. DOI: 10.1186/s12885-019-5951-3. View

10.

Luo Z, Jin H . Effects of LncRNA KCNQ1OT1 on proliferation and migration of ovarian cancer cells by Wnt/β-catenin. Eur Rev Med Pharmacol Sci. 2019; 23(20):8788-8794. DOI: 10.26355/eurrev_201910_19273. View

11.

Miao Y, Li S, Yan Q, Li B, Feng Y . Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Oncol Res Treat. 2016; 39(11):712-719. DOI: 10.1159/000452263. View

12.

Cao C, Zhong Q, Lu L, Huang B, Li J, Meng L . Long noncoding RNA MSC-AS1 promotes hepatocellular carcinoma oncogenesis via inducing the expression of phosphoglycerate kinase 1. Cancer Med. 2020; 9(14):5174-5184. PMC: 7367619. DOI: 10.1002/cam4.3080. View

13.

Li L, Mao X, Qin X, Zhou M, Xing H, Dong F . Aspirin inhibits growth of ovarian cancer by upregulating caspase-3 and downregulating bcl-2. Oncol Lett. 2019; 17(5):4742. PMC: 6444002. DOI: 10.3892/ol.2019.10108. View

14.

Tang X, Yang M, Wang Z, Wu X, Wang D . MicroRNA-23a promotes colorectal cancer cell migration and proliferation by targeting at MARK1. Acta Biochim Biophys Sin (Shanghai). 2019; 51(7):661-668. DOI: 10.1093/abbs/gmz047. View

15.

Yao H, Yang L, Tian L, Guo Y, Li Y . LncRNA MSC-AS1 aggravates nasopharyngeal carcinoma progression by targeting miR-524-5p/nuclear receptor subfamily 4 group A member 2 (NR4A2). Cancer Cell Int. 2020; 20:138. PMC: 7189691. DOI: 10.1186/s12935-020-01202-1. View

16.

Palmqvist C, Staf C, Mateoiu C, Johansson M, Albertsson P, Dahm-Kahler P . Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020; 159(2):409-417. DOI: 10.1016/j.ygyno.2020.09.004. View

17.

Quan J, Li Y, Pan X, Lai Y, He T, Lin C . Oncogenic miR-425-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Oncol Lett. 2018; 16(2):2175-2184. PMC: 6036448. DOI: 10.3892/ol.2018.8948. View

18.

Torres D, Wang C, Kumar A, Bakkum-Gamez J, Weaver A, McGree M . Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability. Gynecol Oncol. 2018; 150(2):227-232. PMC: 8251658. DOI: 10.1016/j.ygyno.2018.06.002. View

19.

Meyer L, He W, Sun C, Zhao H, Wright A, Suidan R . Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018; 150(3):451-459. PMC: 8328050. DOI: 10.1016/j.ygyno.2018.06.020. View

20.

C Grossman D, Curry S, Owens D, Barry M, Davidson K, Doubeni C . Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(6):588-594. DOI: 10.1001/jama.2017.21926. View